Intelligence / Healthtech / New Clinical Trials / Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
27 Oct 2026: Trial registered · A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 27 Oct 2026
- Title
- A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB)
- Conditions
- Chronic Hepatitis B
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Reference
- NCT07897448
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Grand Theravac Life Sciences (Hangzhou) Co., Ltd.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.